Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study
暂无分享,去创建一个
Shoaib Afzal | Jonas Krogh Jensen | Morten Petersen | C. Torp-Pedersen | G. Gislason | H. Poulsen | E. Jimenez‐Solem | K. Broedbaek | Christian Torp-Pedersen | Gunnar H Gislason | Henrik Enghusen Poulsen | Espen Jimenez-Solem | Jon Traerup Andersen | Kasper Broedbaek | S. Afzal | M. Petersen | Jonas Jensen | J. Andersen | G. Gislason
[1] B. Källén,et al. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data , 2010, Psychological Medicine.
[2] P. Mortensen,et al. The Danish Civil Registration System. A cohort of eight million persons. , 2006, Danish medical bulletin.
[3] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2007, Preventive medicine.
[4] A. Bérard,et al. Duration of antidepressant use during pregnancy and risk of major congenital malformations , 2008, British Journal of Psychiatry.
[5] Wilhelmina S Kerstjens-Frederikse,et al. First-trimester use of paroxetine and congenital heart defects: a population-based case-control study. , 2009, Birth defects research. Part A, Clinical and molecular teratology.
[6] T. F. Andersen,et al. The Danish National Hospital Register. A valuable source of data for modern health sciences. , 1999, Danish medical bulletin.
[7] H. Sørensen,et al. Maternal Use of Selective Serotonin Reuptake Inhibitors and Risk of Congenital Malformations , 2006, Epidemiology.
[8] R. Davis,et al. Outcomes of prenatal antidepressant exposure. , 2002, The American journal of psychiatry.
[9] Jan M Friedman,et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. , 2007, The New England journal of medicine.
[10] I. Petersen,et al. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. , 2012, Obstetrics and gynecology.
[11] R. Platt,et al. Use of antidepressant medications during pregnancy: a multisite study. , 2008, American journal of obstetrics and gynecology.
[12] L. Køber,et al. The pattern of use of non‐steroidal anti‐inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people , 2008, Pharmacoepidemiology and drug safety.
[13] B. Källén,et al. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. , 2007, Birth defects research. Part A, Clinical and molecular teratology.
[14] T. Einarson,et al. Incidence of Major Malformations in Infants following Antidepressant Exposure in Pregnancy: Results of a Large Prospective Cohort Study , 2009, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[15] B. Källén,et al. Delivery outcome after the use of antidepressants in early pregnancy , 1999, European Journal of Clinical Pharmacology.
[16] J. Olsen,et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study , 2009, BMJ : British Medical Journal.
[17] J. Olsen,et al. The Danish Medical Birth Registry. , 1998, Danish medical bulletin.
[18] Tara R. Lang,et al. Recent trends in selective serotonin reuptake inhibitor use in pregnancy. , 2008, Journal of clinical psychopharmacology.
[19] L. de Jong-van den Berg,et al. Do Pregnant Women Report Use of Dispensed Medications? , 2001, Epidemiology.
[20] S. Rasmussen,et al. Patterns of Antidepressant Medication Use Among Pregnant Women in a United States Population , 2011, Journal of clinical pharmacology.
[21] Paul B van den Berg,et al. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands. , 2008, British journal of clinical pharmacology.
[22] M. Clementi,et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. , 2008, British journal of clinical pharmacology.
[23] W. Ray,et al. Increasing use of antidepressants in pregnancy. , 2008, American journal of obstetrics and gynecology.
[24] S. Hernández-Díaz,et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. , 2007, The New England journal of medicine.
[25] T. Einarson,et al. Prevalence of Depression During Pregnancy: Systematic Review , 2004, Obstetrics and gynecology.
[26] C. Hertzman,et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. , 2008, Birth defects research. Part B, Developmental and reproductive toxicology.
[27] H. Sørensen,et al. Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. Europen Medicine and Pregnancy Group. , 1999, Teratology.
[28] C. Even,et al. [Antepartum depression: prevalence, diagnosis and treatment]. , 2010, L'Encephale.
[29] S. Sabroe,et al. Identification of patients treated with strong analgesics: An assessment of two Danish information systems with respect to epidemiological research , 1996, Journal of Medical Systems.
[30] R. Platt,et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy , 2007, Pharmacoepidemiology and drug safety.
[31] A. Olshan,et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. , 2010, Birth defects research. Part A, Clinical and molecular teratology.
[32] T. Einarson,et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. , 2007, Clinical therapeutics.
[33] Mark Walker,et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. , 2006, American journal of obstetrics and gynecology.
[34] Eurocat. European Surveillance of Congenital Anomalies (EUROCAT) , 2012 .
[35] Lucie Blais,et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. , 2007, Birth defects research. Part B, Developmental and reproductive toxicology.
[36] C. Pedersen,et al. The Danish Civil Registration System , 2011, Scandinavian journal of public health.
[37] H. Sørensen,et al. The Danish prescription registries. , 1997, Danish medical bulletin.
[38] Tara R. Lang,et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. , 2009, Mayo Clinic proceedings.
[39] M. Nørgaard,et al. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis , 2010, Clinical epidemiology.
[40] K. Ormond,et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. , 1998, JAMA.
[41] P. Neuvonen,et al. Risks Associated With Selective Serotonin Reuptake Inhibitors in Pregnancy , 2005, Obstetrics and gynecology.
[42] L. Jong‐van den Berg,et al. Prevalence and patterns of antidepressant drug use during pregnancy , 2006, European Journal of Clinical Pharmacology.
[43] B. Källén,et al. Antidepressant drugs during pregnancy and infant congenital heart defect. , 2006, Reproductive toxicology.
[44] S. Ephross,et al. Paroxetine in the first trimester and the prevalence of congenital malformations , 2007, Pharmacoepidemiology and drug safety.
[45] B. Källén,et al. Delivery Outcome in Relation to Maternal Use of Some Recently Introduced Antidepressants , 2007, Journal of clinical psychopharmacology.